Free Trial

Q1 Earnings Estimate for MacroGenics Issued By HC Wainwright

MacroGenics logo with Medical background
Remove Ads

MacroGenics, Inc. (NASDAQ:MGNX - Free Report) - HC Wainwright increased their Q1 2025 earnings per share estimates for MacroGenics in a report released on Tuesday, March 25th. HC Wainwright analyst R. Burns now anticipates that the biopharmaceutical company will post earnings per share of ($0.69) for the quarter, up from their prior estimate of ($0.70). HC Wainwright currently has a "Neutral" rating and a $2.00 target price on the stock. The consensus estimate for MacroGenics' current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for MacroGenics' Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.89) EPS.

MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). The firm had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%.

Separately, StockNews.com cut MacroGenics from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Nine equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $7.38.

Remove Ads

Get Our Latest Analysis on MacroGenics

MacroGenics Trading Down 2.0 %

MGNX stock traded down $0.03 during trading on Thursday, reaching $1.24. The stock had a trading volume of 219,071 shares, compared to its average volume of 1,168,734. The firm has a fifty day moving average price of $2.51 and a 200 day moving average price of $3.15. The company has a market capitalization of $77.92 million, a P/E ratio of -0.78 and a beta of 2.12. MacroGenics has a 1-year low of $1.24 and a 1-year high of $19.54.

Institutional Investors Weigh In On MacroGenics

A number of institutional investors have recently made changes to their positions in the company. Wasatch Advisors LP boosted its holdings in MacroGenics by 37.6% in the fourth quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company's stock worth $11,338,000 after purchasing an additional 952,691 shares during the period. Frazier Life Sciences Management L.P. grew its position in shares of MacroGenics by 5.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,175,665 shares of the biopharmaceutical company's stock valued at $10,321,000 after buying an additional 164,938 shares during the last quarter. Geode Capital Management LLC raised its stake in MacroGenics by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,433,217 shares of the biopharmaceutical company's stock worth $4,659,000 after acquiring an additional 26,341 shares during the period. Two Sigma Advisers LP lifted its holdings in MacroGenics by 7.1% in the fourth quarter. Two Sigma Advisers LP now owns 1,118,600 shares of the biopharmaceutical company's stock worth $3,635,000 after acquiring an additional 74,596 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in MacroGenics in the fourth quarter valued at approximately $2,787,000. 96.89% of the stock is currently owned by institutional investors.

About MacroGenics

(Get Free Report)

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Featured Stories

Should You Invest $1,000 in MacroGenics Right Now?

Before you consider MacroGenics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.

While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Quantum Stocks Are Heating Up Again — 7 to Watch Now

Quantum Stocks Are Heating Up Again — 7 to Watch Now

After a brief dip earlier this year, fresh momentum has reignited interest; from penny plays to tech giants, these quantum stocks could lead the next surge.

Related Videos

Elon Musk’s First 100 Days of DOGE: 3 AI Stocks Ready to Soar
Pelosi Bets Big on AI: Her Top 5 Stock Picks
The Future of Healthcare: 3 AI Stocks Leading the Way

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads